Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

PURPOSE: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, “endogenous” biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Park, Steven I., Shenoi, Jaideep, Frayo, Shani M., Hamlin, Donald K., Lin, Yukang, Wilbur, D. Scott, Stayton, Patrick S., Orgun, Nural, Hylarides, Mark, Buchegger, Franz, Kenoyer, Aimee L., Axtman, Amanda, Gopal, Ajay K., Green, Damian J., Pagel, John M., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3229652/
https://ncbi.nlm.nih.gov/pubmed/21976541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados